Entera Bio LtdJerusalem, Yerushalayim, Israel
Disclosure information not submitted.
SAT-677 - EB618, First-in-Class Oral Tablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and Metabolic Disorders: Results from PK-PD Study in Non-Human Primates
Saturday, June 13, 20269:30 AM - 4:30 PM CT
ORF37-02 - Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study
Sunday, June 14, 20263:30 PM - 4:15 PM CT
MON-768 - Pre-Clinical Results for EB612: First-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet for Patients with Hypoparathyroidism
Monday, June 15, 20269:00 AM - 2:00 PM CT
.jpg)
.jpg)